Liver/Biliary Disorders News

Topline findings from the phase 3 D-LIVR trial showed that lonafarnib — boosted with ritonavir and in combination with peginterferon alfa — improved responses in patients with chronic hepatitis D virus, Eiger BioPharmaceuticals announced.

WASHINGTON — The term ‘non-alcoholic fatty liver disease’ no longer reflects current knowledge of the disease and should be changed, members of the NAFLD Nomenclature steering committee noted during The Liver Meeting.

WASHINGTON — A leading expert in hepatology called for fellow specialists to embrace a role of education, advocacy and support as part of a proposed national hepatitis C virus elimination program presented during The Liver Meeting.

WASHINGTON — Vosevi, a triple-combination therapy for chronic hepatitis C virus infection, was effective when used as a rescue treatment in patients who did not achieve sustained virologic response with direct-acting antiviral agents.

The Liver Meeting 2022 delivered the latest research and developments on a variety of topics, including acute hepatitis in children, treatment for hepatitis-related cirrhosis and liver disease mortality during the COVID-19 pandemic.

Adults with nonalcoholic fatty liver disease and severe obesity have a lower risk for cardiovascular disease if they undergo bariatric surgery vs. those who do not have surgery, according to study findings published in JAMA Network Open.

Clinical and imaging findings of children with type 1 diabetes and obesity were similar to those for children without diabetes with similar degrees of obesity, according study results published in Journal of Diabetes and its Complications.

CHARLOTTE, N.C. — Early palliative care referral would benefit patients with end-stage liver disease, resulting in fewer hospitalizations and more health care proxy assignments and code status changes, according to a presenter here.

CHARLOTTE, N.C. — Elevated ferritin correlated with an increased prevalence of cirrhosis — but not congestive heart failure — in patients with metabolic dysfunction-associated fatty liver disease, according to a presenter here.

CHARLOTTE, N.C. — A subgroup analysis of liver transplant patients with hepatorenal syndrome type 1 demonstrated that terlipressin decreased the need for renal replacement therapy up to 12 months following transplantation.